Medifast

Medifast, Inc. engages in the provision of healthy living products and programs. It offers the OPTAVIA brand, a lifestyle solution centered on developing new healthy habits through smaller, foundational changes called micro-habits. The firm’s product line includes bars, bites, pretzels, puffs, cereal crunch, drinks, hearty choices, oatmeal, pancakes, pudding, soft serve, shakes, smoothies, soft bakes, and soups. The company was founded by William Vitale in 1981 and is headquartered in Baltimore, MD.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Medifast reports Q4 revenue decline, focuses on cost management

Medifast's Q4 2022 performance saw revenue decline but strong cost management and cash generation.
Challenges include revenue outlook for Q1 2023 and competitive landscape in weight loss and coaching markets.
Opportunities lie in capital allocation strategies, maintaining shareholder value, and adapting to market trends.
Overall, Medifast remains focused on long-term growth, financial stability, and delivering on its mission.

Medifast surpasses Q1 expectations, eyes growth amid operational tweaks

Medifast's Q1 2023 performance exceeded expectations, with a focus on revenue growth and cost control measures.
Despite challenges like decreased active coaches, the company is well-positioned with a strong financial standing and growth initiatives.
Opportunities in customer acquisition, cost-saving efforts, market expansion, and innovative solutions pave the way for future success.
Guidance for Q2 2023 reflects a strategic approach to balancing growth and profitability amidst market dynamics and operational changes.

Medifast reports Q2 revenue decline, eyes sustainable growth strategies

Medifast navigated challenges in Q2 2023 with improved operating margin and strategic market exits.
The company's focus on new growth initiatives and cost-saving measures reflects adaptability to market dynamics.
While facing revenue declines and competitive pressures, Medifast aims for sustainable growth with clear targets.
Exploration of medically supported weight loss solutions and new product lines offer avenues for future expansion.

Medifast reports resilient Q3 performance, eyes growth through diversification

Medifast's Q3 performance reflects resilience amid revenue decline, with a focus on operational efficiency and financial strength. While facing challenges in revenue and expense management, the company remains agile and proactive in exploring growth opportunities through market expansion and social responsibility initiatives.

Medifast transitions to health and wellness focus amidst revenue challenges

Medifast is navigating challenges in customer acquisition and macro factors while focusing on becoming a diversified health and wellness company.
The company's strategic collaboration with Life MD and new product offerings position it for growth.
While Q4 2023 saw a revenue decrease, Medifast's improved gross profit margin and cost-saving initiatives demonstrate operational efficiency.
Investors should monitor the impact of increased marketing spending on operating margin and EPS in the coming years.

Medifast faces revenue decline due to weight loss medication trends

Medifast's Q1 2024 performance reflects challenges in revenue and income, driven by difficulties in customer acquisition amidst weight loss medication trends.
Despite the decline, the company demonstrated operational efficiency with improved gross profit margins and cost management.
Investments in marketing and collaborations present opportunities for future growth and market expansion, signaling a strategic focus on long-term success.
Navigating market challenges while capitalizing on opportunities will be crucial for Medifast's resilience and competitiveness in the weight loss industry.

Medifast reports Q2 losses, focuses on growth strategies and cost management

Medifast's Q2 2024 performance reflects a challenging period marked by revenue and profit declines, offset by margin improvements and cost reductions.
The company's strategic initiatives aim to drive long-term growth and enhance operational efficiency amidst macroeconomic headwinds and lower coach productivity.
While facing financial setbacks, Medifast's focus on targeted advertising, product diversification, and cost management signifies a proactive stance towards future recovery and growth.

Medifast adapts to industry changes with tailored programs and innovations

Medifast's Q3 2024 performance reflected revenue and net income declines, highlighting challenges in the weight loss industry.
Despite these challenges, the company's strategic focus on tailored programs, strong financial position, and new product launches indicate a proactive approach to addressing market dynamics.
Opportunities in clinical studies, new product launches, and financial strength position Medifast for potential growth and market expansion in the future.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Medifast, Inc. engages in the provision of healthy living products and programs. It offers the OPTAVIA brand, a lifestyle solution centered on developing new healthy habits through smaller, foundational changes called micro-habits. The firm's product line includes bars, bites, pretzels, puffs, cereal crunch, drinks, hearty choices, oatmeal, pancakes, pudding, soft serve, shakes, smoothies, soft bakes, and soups. The company was founded by William Vitale in 1981 and is headquartered in Baltimore, MD.

Medifast's (MED) third-quarter results are likely to reflect gains from consumers' increased inclination toward health products amid the pandemic. However, high costs are a concern.

Here's How Medifast (MED) Looks Just Ahead of Q3 Earnings

BALTIMORE, Oct. 20, 2020 /PRNewswire/ -- Medifast, Inc. (NYSE: MED), the company behind one of the fastest-growing health and wellness communities, OPTAVIA®, will announce financial results for the third quarter ended September 30, 2020 on Monday, November 2, 2020, after market close. The...

Medifast, Inc. to Announce Financial Results for the Third Quarter Ended September 30, 2020

Medifast's (MED) OPTAVIA lifestyle solution bodes well amid evolving consumer interests in health and wellness. However, rising costs are a concern.

Medifast Gains on Strength in OPTAVIA, Cost Concerns Stay

Medifast (MED) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Why Medifast (MED) is Poised to Beat Earnings Estimates Again

Columbia Sportswear Company

Edwards Lifesciences

Masimo

Mastech Digital

According to the All-in-One Screener, a Premium feature of GuruFocus, five stalwarts that have high financial strength and expanding operating margins include Mastech Digital Inc. (MHH), Columbia Sportswear Co. (NASDAQ:COLM), Medifast Inc. (NYSE:MED), Masimo Corp. (NASDAQ:MASI) and Edwards Lifesciences Corp. (NYSE:EW).

5 Peter Lynch Stalwarts With Expanding Profit Margins

1-800-FLOWERS.COM

Installed Building Products

Nu Skin Enterprises

Zumiez

Here are five top-ranked liquid stocks, including Nu Skin Enterprises (NUS), that investors can snap up for enhancing portfolio returns.

Bet on These 5 Top-Ranked Liquid Stocks for Fat Returns

Nathan's Famous

Grupo Aeroportuario del Centro Norte

Winmark

Stocks with strong fundamentals and attractive valuations based on exclusive method

4 Good Companies Trading at Fair GuruFocus Value

Virtusa

Here are four top-ranked liquid stocks, including Zumiez (ZUMZ), that investors can bank on for alluring returns.

4 Promising Top-Ranked Liquid Stocks to Enrich Your Portfolio

Griffon

Scotts Miracle-Gro

Stewart Information Services

Target

Volatility may persist for a few more days. However, the worst of Wall Street is long over and the overall market movement should remain positive going forward.

5 Top-Ranked High-Yielding Growth Stocks for September

Mr. Cooper Group Inc

eHealth

M/I Homes

Several stocks skyrocketed last week and a handful of these were Zacks top-ranked.

6 Top-Ranked Stocks That Surged More Than 10% Last Week

Medifast (MED) possesses solid growth attributes, which could help it handily outperform the market.

Here is Why Growth Investors Should Buy Medifast (MED) Now

Logitech

Here are four excellent liquid stocks, including Logitech (LOGI), that can contribute to making an outstanding portfolio for investors.

4 Best-Performing Liquid Stocks for Alluring Returns

FormFactor

Liquidity Services

Stride

Zoom Video

It's a good time to invest in growth stocks, but it's a better idea to see that they have the financial strength to snap out of any difficult situation if it arises.

5 Growth Stocks With Strong Balance Sheets

With a current revenue of nearly $400 million, it is now clear the company will exceed its original revenue guidance.

Medifast Is The One That Got Away

Medifast's (MED) second-quarter 2020 results reflect solid earnings and sales. Strong OPTAVIA performance, thanks to a substantial rise in active earning coaches, boosted results.

Medifast (MED) Q2 Earnings Top Estimates on OPTAVIA Strength

Medifast, Inc. (MED) CEO Dan Chard on Q2 2020 Results - Earnings Call Transcript

Medifast (MED) delivered earnings and revenue surprises of 6.52% and 12.97%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Medifast (MED) Beats Q2 Earnings and Revenue Estimates

Camping World Hlds

Fiserv

Fastly

Global Blood Therapeutics

ResMed

Cimarex Energy

Seven top-ranked companies are poised to beat on earnings today after the closing bell.

Top 7 Stocks Set to Beat on Earnings Today After Market

Fastenal

Innovative Industrial Properties

3 Dividend Stocks Killing It This Year (They Are Not Tech Stocks Or Gold)

Strength in OPTAVIA brand is likely to get reflected in Medifast's (MED) second-quarter 2020 performance. However, rising SG&A expenses is a concern.

What's in the Cards for Medifast (MED) This Earnings Season?

Flowers Foods

Ollie's Bargain Outlet Hlds

Reynolds Consumer Products

The gradual easing of restrictions followed by the opening of the economy will boost spending which had hit rock bottom over the past few of months.

4 Essential Goods Stocks to Tap the Rise in Consumer Spending

B&G Foods

Monster Beverage

The consumer staples sector has so far reported relatively better results despite the decline of overall sector's earnings year over year.

Top 5 Consumer Staple Stocks Ahead of Q2 Earnings Results

BALTIMORE, July 22, 2020 /PRNewswire/ -- Medifast, Inc. (NYSE: MED), the company behind one of the fastest-growing health and wellness communities, OPTAVIA®, will announce financial results for the second quarter ended June 30, 2020 on Wednesday, August 5, 2020, after market close.

Medifast, Inc. to Announce Financial Results for the Second Quarter Ended June 30, 2020

Artisan Partners Asset Management

Broadmark Realty Capital Inc.

Blackstone Mortgage Trust

Ladder Capital

Luminex

Public Service Enterprise Group

PetMed Express

Pfizer

Charles Schwab

Nate Pile — the editor of growth stock advisory Nate's Notes has just released the first issue of a new advisory service focused on retirement investing, The Little River Investment Guide. The advisor reviews the initial 12 stocks that will make up his income-generating retirement portfolio.

12 Stocks For An Income Generating Retirement Portfolio

As of late, it has definitely been a great time to be an investor of Medifast

Will Medifast Continue to Surge Higher?

News for Medifast Stock (MED)